BCL2 and cancer: Because Bcl-2 inhibitors bind to Mcl-1 with low affinity, Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in multiple cancer types, including non-small cell lung cancer (NSCLC) and acute myeloid leukemia8,9.